【摘要】 目的：分析川芎嗪注射液联合纤溶酶注射液在急性脑梗死（ACI）患者治疗中的应用价值。方法：选取2020年9月—2022年1月我院收治的94例ACI患者，根据随机数字表法分为对照组、联合组，各47例。所有患者均给予常规治疗，对照组给予纤溶酶注射液，联合组在对照组基础上给予川芎嗪注射液治疗。比较两组临床疗效、凝血四项指标[活化部分凝血酶原时间（APTT）、凝血酶原时间（PT）、凝血酶时间（TT）、纤维蛋白原（FIB）]、血清D-二聚体（D-D）、同型半胱氨酸（Hcy）、神经胶质纤维酸性蛋白（GFAP）、重组人帕金森病蛋白7(PARK7)水平、美国国立卫生院卒中量表（NIHSS）评分、脑卒中专用生活质量量表（SS-QOL）评分及不良反应发生情况。结果：联合组总有效率为93.62%，高于对照组的74.47%(P<0.05)；联合组APTT、TT、PT高于对照组，FIB低于对照组（P<0.05）；联合组血清D-D、Hcy、GFAP、PARK7低于对照组（P<0.05）；联合组NIHSS评分低于对照组，SS-QOL评分高于对照组（P<0.05）；联合组不良反应总发生率与对照组比较，差异无统计学意义（P>0.05）。结论：川芎嗪注射液联合纤溶酶注射液治疗效果显著，能调节ACI患者血清指标水平，减轻神经缺损程度，有助于提高患者生活质量。更多还原

【Abstract】 Objective: To analyze the application value of ligustrazine injection combined with plasmin injection in the treatment of patients with acute cerebral infarction(ACI). Methods: A total of 94 ACI patients admitted to our hospital from September 2020 to January 2022 were selected and divided into control group and combined group according to random number table method, with 47 cases in each group. All patients were given routine treatment, the control group was given fibrinolytic enzyme injection, and the combined group was given ligustrazine injection on the basis of the control group. The clinical efficacy, four coagulation indexes [activated partial thromboplastin time(APTT), prothrombin time(PT), thrombin time(TT), fibrinogen(FIB)], serum D-dimer(D-D), homocysteine(Hcy), glial fibrillary acidic protein(GFAP), recombinant human Parkinson’s disease protein 7(PARK7) level, National Institutes of Health Stroke Scale(NIHSS) score, Strokespecific Quality of Life Scale(SS-QOL score) and adverse reactions were compared between the two groups. Results: The total effective rate of the combined group was 93.62%, which was higher than 74.47% of the control group(P<0.05). APTT,TT and PT in the combined group were higher than those in the control group, and FIB was lower than that in the control group(P<0.05). Serum D-D, Hcy, GFAP and PARK7 in the combined group were lower than those in the control group(P<0.05). The NIHSS score of the combined group was lower than that of the control group, and the SS-QOL score was higher than that of the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the combined group and the control group(P>0.05). Conclusion: Ligustrazine injection combined with plasmin injection has a significant therapeutic effect, which can regulate the serum index level of ACI patients, reduce the degree of nerve defect, and help to improve the quality of life of patients.更多还原